-

Northlane Capital Partners Closes Fund II at $408 Million

BETHESDA, Md.--(BUSINESS WIRE)--Northlane Capital Partners (“Northlane” or “NCP”), a middle market private equity firm targeting investments in healthcare and business services, today announced that it has successfully raised its second independent fund, Northlane Capital Partners II, L.P. (“NCP II” or “Fund II”). NCP II closed on total capital commitments of $408 million, exceeding its target of $375 million, and attracted strong interest from a diverse group of investors, including public pension funds, asset managers, insurance companies, high net worth families, foundations, and former portfolio company executives.

Fund II will continue Northlane’s strategy of targeting niche outsourced service providers in its two industry verticals that we believe demonstrate consistent performance across economic cycles and operate in subsectors poised to benefit from secular growth. The four founding partners have worked together since 2003 and have completed 27 platform investments. Fund II has already invested in two companies – VMG Health, a valuation and transaction advisory firm exclusively focused on the healthcare industry, and Empower Community Care, a global behavioral health organization responsible for distributing evidence-based programs and technologies that seek to transform the lives of troubled youth, their families, and communities. Since NCP II’s initial investment, VMG Health has completed two add-on acquisitions.

About Northlane Capital Partners

Based in Bethesda, MD, NCP is a middle market private equity firm focused on key segments within the healthcare and business services sectors, where its principals have invested more than $1.5 billion of equity capital. NCP’s strategy is to partner with industry leading companies and great management teams, aligning incentives to accelerate growth and build value. NCP was recently named to Inc.'s 2020 Private Equity 50 list of the top founder-friendly private equity firms. For more information, please visit www.northlanecapital.com

Contacts

Justin DuFour, Sean Eagle, Eugene Krichevsky, and David Steinglass
Northlane Capital Partners
2 Bethesda Metro Center, Suite 1510
Bethesda, MD 20814
301-272-9990

Northlane Capital Partners


Release Summary
Northlane Capital Partners Closes Fund II at $408 Million
Release Versions

Contacts

Justin DuFour, Sean Eagle, Eugene Krichevsky, and David Steinglass
Northlane Capital Partners
2 Bethesda Metro Center, Suite 1510
Bethesda, MD 20814
301-272-9990

More News From Northlane Capital Partners

Northlane Capital Partners Announces Investment in Plus Delta Partners

CARLSBAD, Calif.--(BUSINESS WIRE)--Northlane Capital Partners (“NCP”) announced today that it has made an investment in Plus Delta Partners (“PDP”), a leading provider of specialized fundraising training and tools designed to enable higher education institutions, healthcare organizations, and other nonprofits to maximize donor contributions. NCP invested alongside PDP’s management team and its founder, Guy Hart. PDP offers a comprehensive suite of fundraising training solutions tailored to fron...

Northlane Capital Partners Invests in United States Drug Testing Laboratories

DES PLAINES, Ill.--(BUSINESS WIRE)--Northlane Capital Partners (“NCP”) announced today that it has invested in United States Drug Testing Laboratories Inc. (“USDTL”), a forensic toxicology laboratory testing for alcohol and substance use. NCP invested alongside USDTL’s management team and its founders, Veronica and Doug Lewis. USDTL is headquartered in Des Plaines, IL, and offers a broad suite of forensic testing capabilities. The company primarily serves hospitals, health systems, court system...

SAI MedPartners Expands Strategic Service Offering Through Acquisition of IDEA Pharma

READING, Pa.--(BUSINESS WIRE)--SAI MedPartners (“SAI”), a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce that it has acquired IDEA Pharma (“IDEA”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022. IDEA, headquartered in London, United Kingdom, specializes in pharmaceutical path-to-market strategy and innovation. This acquisition strengthens SAI’s ca...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.